Dr. Reddy’s Laboratories informs about disclosure

16 Apr 2025 Evaluate
With reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) regarding a news item published in The Economic Times (newspaper/ media) on April 15, 2025, with the heading ‘Sweet Surrender: Sanofi puts star insulin brand on block’. The said news item states that Sanofi India has started the process of selling its flagship insulin brand, Lantus, with major domestic pharmaceutical companies and has mentioned Dr. Reddy's Laboratories as one of the potential acquirers. In this regard, Dr. Reddy’s Laboratories has informed that the Company does not comment on market speculations and there is currently no such event or information which requires a disclosure under Regulation 30 of the SEBI Listing Regulations. In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosure of any event or information, as and when any event or information is considered material or warrants such disclosure under the said Regulation.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1275.50 -1.50 (-0.12%)
05-Dec-2025 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.15
Dr. Reddys Lab 1275.50
Cipla 1521.80
Zydus Lifesciences 931.80
Lupin 2100.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×